The topic of this article may not meet Wikipedia's notability guideline for academics. (April 2011) (Learn how and when to remove this template message)
Deborah Carmen Mash
|Known for||Ibogaine research|
|Alma mater||Leonard M. Miller School of Medicine|
|Sub-discipline||molecular and cellular pharmacology|
|Institutions||Miller School of Medicine|
Deborah Carmen Mash is an American professor of neurology and of molecular and cellular pharmacology at the Leonard M. Miller School of Medicine, and director of the Brain Endowment Bank at the University of Miami.
Mash became fascinated with the human brain while she was an undergraduate student at Florida State University. After completing a Bachelor of Arts degree there, she completed a Ph.D. program at the Miller School of Medicine at the University of Miami, and did a postdoctoral fellowship at Harvard Medical School's Beth Israel Hospital in Boston, Massachusetts. In 1986 she joined the faculty of her alma mater, the University of Miami.
In 1994, the Food and Drug Administration of the United States granted Mash an Investigational New Drug license, to permit her to research the addiction-stopping capabilities of ibogaine (an oneirogen that occurs in some plants). A lack of funding and other barriers prevented the research from proceeding. Mash and her colleagues had previously discovered that ibogaine is a prodrug that metabolizes into a psychoactive called 12-hydroxyibogamine (or, noribogaine). In the late 1990s she provided some assistance to Healing Transitions Institute for Addiction, a drug detoxification clinic in Cancún where physicians oversaw patients' ibogaine treatments.
On eight occasions between 2005 and 2009, she served as an expert witness for the defense in wrongful death claims filed against electroshock weapon manufacturer TASER International. The company's official position was that the cause of death in Taser fatalities was excited delirium. Dr. Mash performed post-mortem examinations of the brains of people who were allegedly victims of excited delirium, and reported that most of them showed signs of drug abuse—most frequently cocaine or amphetamine.
- Mash, Deborah. "Interesting People: Dr. Deborah Mash" (Interview). The Herbert W. Hoover Foundation. Retrieved 2017-11-23.
- "Deborah Mash". uhealthsystem.com. University of Miami Health System. Retrieved 2017-11-23.
- "Uncovering Ibogaine: The Deborah Mash Interview". Let Them Talk (Interview). Interviewed by Paul De Rienzo. New York. July 1996. Retrieved 2017-11-23.
- "Ibogaine: Treatment Outcomes and Observations" (PDF). 13 (2). Multidisciplinary Association for Psychedelic Studies. 2003: 16. Retrieved 2017-11-23.
- Obembe, Samuel B. (2012). "Practical Skills and Clinical Management of Alcoholism and Drug Addiction". Practical Skills and Clinical Management of Alcoholism and Drug Addiction. Elsevier. p. 90. ISBN 978-0-12-398518-7. Retrieved 2017-11-23.
- Mash, Deborah (May 3, 2010). "Clean, Ibogaine Clean". The Gnostic Media Podcast (Interview). Interviewed by Jan Irvin. Gnostic Media.
- Humberto, Fernandez; Libby, Therissa A. Heroin: Its History, Pharmacology & Treatment. ISBN 978-1-59285-990-0. Retrieved 2017-11-23.
- Szep, Jason; Reid, Tim; Eisler, Peter (August 24, 2017). "How Taser inserts itself into investigations involving its own weapons". Reuters Investigates. Reuters. Retrieved 2017-11-23.
- Miletich, John J.; Lindstrom, Tia Laura. An Introduction to the Work of a Medical Examiner: From Death Scene to Autopsy Suite. Praeger. p. 32. Retrieved 2017-11-23.
- De Rienzo, Paul; Beal, Dana; et al. (1997). "Deborah Mash's Brain". The Ibogaine Story: Report on the Staten Island Project. Autonomedia. ISBN 978-1-57027-029-1. OCLC 36910760. Retrieved 2017-11-23 – via MindVox.